Don't forget PFS understates the likely OS benefits when it comes to the antibody targeting.
Looking very likely that OS will again be shown to br almost 4x that of pluvicto.
Kick arse.
Ann: ProstACT SELECT Study of TLX591 rADC Therapy - Positive rPFS, page-16
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.29 |
Change
-1.030(5.33%) |
Mkt cap ! $6.465B | |||
| Open | High | Low | Value | Volume |
| $18.82 | $18.87 | $17.60 | $13.51M | 740.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 145 | $18.29 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.30 | 1680 | 8 |
View Market Depth
| Last trade - 10.30am 31/07/2024 (20 minute delay) ? |
| TLX (ASX) Chart |